Interferon News and Research

RSS

Study compares breast and bottle fed infants

Infant rhesus monkeys receiving different diets early in life develop distinct immune systems that persist months after weaning, a study by researchers from UC Davis, the California National Primate Research Center (CNPRC) at UC Davis and UC San Francisco have shown.

5 Sep 2014

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has released an update on the clinical trial pipeline for its lead immunotherapy products treating basal cell carcinoma (BCC) and breast cancer.

4 Sep 2014

Scientists aim to develop rapid test system for immune dysfunction to treat cystic fibrosis

Cystic fibrosis (CF) is a frequent genetic disease affecting the lung and the gastrointestinal tract. Scientists from the Helmholtz Zentrum München now have shown that many of the adult patients with CF in addition lack a cell surface molecule, which is important for immune defence. The results have been published recently in the 'Journal of Molecular Medicine'.

4 Sep 2014

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb today announced the launch of Daklinza▼ (daclatasvir) in the UK, a new medicine for the treatment of adult patients with chronic hepatitis C. Daclatasvir, a treatment that works across multiple hepatitis C genotypes, will allow up to 90% of UK patients the option of a potentially curative oral treatment regimen that does not include interferon, a standard of care commonly associated with sustained flu-like side effects.

4 Sep 2014

NASA study reveals how spaceflight affects immune system of crew members

There is nothing like a head cold to make us feel a little dazed. We get things like colds and the flu because of changes in our immune system. Researchers have a good idea what causes immune system changes on Earth-think stress, inadequate sleep and improper nutrition.

19 Aug 2014

Ebola virus defeats attempts by interferon to block viral reproduction in infected cells

One of the human body's first responses to a viral infection is to make and release signaling proteins called interferons, which amplify the immune system response to viruses.

14 Aug 2014

Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate has been approved since January 2014 for adults with relapsing remitting multiple sclerosis.

8 Aug 2014

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet.

29 Jul 2014

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Telaprevir to the market, an innovative therapy that significantly increases the cure rate from Hepatitis C, and it is indicated for patients infected with the genotype 1 virus. Telaprevir is available in Trinidad under the trade brand INCIVO®.

26 Jul 2014

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in the July, 2014 Rhode Island Medical Journal special edition, "RI Defeats Hep C" that eliminating hepatitis c virus infection (hep c or HCV) is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities.

26 Jul 2014

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 Jul 2014

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Gaston Picchio outlines the major findings of the recent report published by The Economist Intelligence Unit (EIU): ‘Tackling hepatitis C: Moving towards an integrated policy approach’

23 Jul 2014

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

A multicenter team of researchers report that in a phase III clinical trial, a combination drug therapy cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C.

21 Jul 2014

Investigators identify gene that underlies devastating autoinflammatory condition in children

Investigators have identified a gene that underlies a very rare but devastating autoinflammatory condition in children. Several existing drugs have shown therapeutic potential in laboratory studies, and one is currently being studied in children with the disease, which the researchers named STING-associated vasculopathy with onset in infancy (SAVI).

17 Jul 2014

Transcription factor IRF4 plays key role in brown fat's thermogenic process

The body contains two types of fat cells, easily distinguished by color: White and brown. While white fat serves to store excess calories until they're needed by the body, brown adipocytes actually burn fat by turning it into heat.

4 Jul 2014

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

30 Jun 2014

Host-directed therapy: A new type of TB treatment

In a new study published in Nature, scientists describe a new type of tuberculosis (TB) treatment that involves manipulating the body's response to TB bacteria rather than targeting the bacteria themselves, a concept called host-directed therapy.

28 Jun 2014

EMA CHMP adopts positive opinion for Bristol-Myers Squibb’s Daklinza for HCV treatment

Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.

27 Jun 2014

New article explores how specific types of interferons control RNA virus infection

Respiratory and intestinal infections caused by RNA viruses stimulate infected cells to produce interferons, which can act alone or in combination to block virus replication.

27 Jun 2014

Interactions with other infections can trigger herpes virus to reactivate, shows research

The famous slogan is "A diamond is forever," but that phrase might be better suited to herpes: Unlike most viruses, which succumb to the immune system's attack, herpes remains in the body forever, lying in wait, sometimes reactivating years later.

27 Jun 2014

Interferon News and Research

Study compares breast and bottle fed infants

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Scientists aim to develop rapid test system for immune dysfunction to treat cystic fibrosis

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

NASA study reveals how spaceflight affects immune system of crew members

Ebola virus defeats attempts by interferon to block viral reproduction in infected cells

Dimethyl fumarate offers no added benefits for adults with RRMS

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Trinidad & Tobago Ministry of Health approves hepatitis C drug telaprevir

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Combination drug therapy cures chronic hepatitis C in co-infected HIV patients

Investigators identify gene that underlies devastating autoinflammatory condition in children

Transcription factor IRF4 plays key role in brown fat's thermogenic process

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Host-directed therapy: A new type of TB treatment

EMA CHMP adopts positive opinion for Bristol-Myers Squibb’s Daklinza for HCV treatment

New article explores how specific types of interferons control RNA virus infection

Interactions with other infections can trigger herpes virus to reactivate, shows research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News